This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Tyme Technologies Crecimiento futuro

Future controles de criterios 0/6

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

Sep 15

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Nov 19

Tyme Technologies: The Market Missed The Bullish Memo

Aug 27

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Jul 19

Tyme Technologies reports FY results

Jun 10

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

May 29

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Mar 26

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Feb 19

Tyme falls after equity offer as quarterly data indicate liquidity pressure

Feb 04

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Feb 03

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Feb 02

Revisiting Tyme Technologies

Dec 17

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

Dec 16

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

Dec 09

Tyme Technologies names new finance chief

Nov 30

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Tyme Technologies no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:TYME - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2022	N/A	-24	-20	-20	N/A
3/31/2022	N/A	-24	-21	-21	N/A
12/31/2021	N/A	-24	-19	-19	N/A
9/30/2021	N/A	-25	-21	-21	N/A
6/30/2021	N/A	-26	-23	-23	N/A
3/31/2021	N/A	-29	-24	-24	N/A
12/31/2020	N/A	-28	-24	-24	N/A
9/30/2020	N/A	-28	-23	-23	N/A
6/30/2020	N/A	-28	-20	-20	N/A
3/31/2020	N/A	-22	-20	-20	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-29	-19	-19	N/A
6/30/2019	N/A	-29	-19	-19	N/A
3/31/2019	N/A	-33	-20	-20	N/A
12/31/2018	N/A	-27	-20	-20	N/A
9/30/2018	N/A	-25	-17	-17	N/A
6/30/2018	N/A	-23	-15	-15	N/A
3/31/2018	N/A	-19	-12	-12	N/A
12/31/2017	N/A	-17	-10	-10	N/A
9/30/2017	N/A	-14	-9	-9	N/A
6/30/2017	N/A	-12	-7	-7	N/A
3/31/2017	N/A	-15	-6	-6	N/A
12/31/2016	N/A	-17	-6	-6	N/A
6/30/2016	N/A	-13	-6	-6	N/A
3/31/2016	N/A	-11	N/A	-5	N/A
12/31/2015	N/A	-12	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Insufficient data to determine if TYME's forecast earnings growth is above the savings rate (1.9%).

Beneficios vs. Mercado: Insufficient data to determine if TYME's earnings are forecast to grow faster than the US market

Beneficios de alto crecimiento: Insufficient data to determine if TYME's earnings are expected to grow significantly over the next 3 years.

Ingresos vs. Mercado: Insufficient data to determine if TYME's revenue is forecast to grow faster than the US market.

Ingresos de alto crecimiento: Insufficient data to determine if TYME's revenue is forecast to grow faster than 20% per year.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Insufficient data to determine if TYME's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Tyme Technologies Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased to US$9.44

Recent updates

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from NASDAQ Composite Index

Tyme Technologies, Inc. Announces Board Changes

Syros, Tyme Technologies jump more than 20% after hours as shareholders approve merger

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

TYME stock surges on merger agreement and Syros Pharmaceuticals

Tyme Technologies Receives Extension to Regain Compliance with the Nasdaq Continued Listing Standards

Tyme Technologies: Net-Net Biopharma Exploring Strategic Alternatives

Co-Founder & Director notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Insufficient new directors

Insufficient new directors

We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business Growth

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. to Report Q3, 2022 Results on Feb 11, 2022

Tyme Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer

Tyme Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections

Tyme Technologies Offers Incredible Risk-Reward

Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Co-Founder notifies of intention to sell stock

TYME Technologies, Inc. Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Independent Director recently bought US$52k worth of stock

Tyme Technologies: The Market Missed The Bullish Memo

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn Rate

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from Russell 3000 Growth Index

Tyme Technologies reports FY results

Tyme Technologies: Recent Sell-Off Provides Opportunity To Buy At A Discount

Co-Founder notifies of intention to sell stock

Price target increased to US$9.44

Chief Medical Officer has left the company

Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn Situation

Insider recently sold US$55k worth of stock

Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?

Insider recently sold US$55k worth of stock

Tyme falls after equity offer as quarterly data indicate liquidity pressure

New 90-day high: US$3.53

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?

Co-Founder notifies of intention to sell stock

New 90-day high: US$1.34

Revisiting Tyme Technologies

Co-Founder recently sold US$613k worth of stock

Co-Founder notifies of intention to sell stock

Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?

Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?

Tyme Technologies, Inc. Announces Executive Changes

New 90-day high: US$1.05

Tyme Technologies names new finance chief

Tyme Technologies, Inc. Announces Resignation of Ben R. Taylor as Chief Financial Officer

New 90-day low: US$0.92

Co-Founder notifies of intention to sell stock

Tyme Technologies, Inc. Announces Executive Changes

New 90-day low - US$0.98

New 90-day low - US$1.17

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento